Entity

Oncostellae

Pharma

 

Oncostellae is a clinical-stage biopharmaceutical company focused on the discovery and development of proprietary drug candidates with strong IP and worldwide rights targeting indications in oncology and immunology with high unmet medical need.

 

The lead program is a novel, GI-targeted JAK inhibitor, OST-122, which is currently in clinical development for the treatment of IBD (Inflammatory Bowel Disease). OST-122 acts exclusively in the gastrointestinal tract avoiding severe systemic toxicities inherent in other JAK inhibitors. Its excellent safety profile has been demonstrated in preclinical models, healthy volunteers during a successful phase 1 clinical trial, and currently in a phase 2a proof-of-concept study in patients with Ulcerative colitis.

 

A second clinical program focuses on the development of OST-499, a non-steroidal full antagonist of the glucocorticoid receptor, which is currently in a phase 1 clinical trial in patients with colorectal cancer or other solid tumors.

+34 617 640 327

guido.kurz@oncostellae.com

oncostellae.com


Contact person: Guido Kurz

Location: Torre I - 03A1